1. ITALIC
Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet therapy (DAPT). Patients were followed for 1 year.
Results
(p = )*
MACE for short-term vs. long-term DAPT: 1.5% vs. 1.6%, pnoninferiority = , psuperiority = 0.85
MI: 0.7% vs. 0.4%, p = 0.53; stent thrombosis: 0.3% vs. 0%, p > 0.05; all-cause mortality: 0.9% vs. 0.8%, p = 0.8
Major bleeding: 0 vs. 0.3%; minor bleeding: 0.5% vs. 0.4%, p > 0.05 for both %
Conclusions
Shorter durations of DAPT (6 months) noninferior to longer durations of DAPT in patients undergoing EES PCI in mostly low-risk patients
This trial was terminated early; thus, the results are likely underpowered
MACE
* For noninferiority
Short-term DAPT
(n = 926)
Long-term DAPT
(n = 924)
Gilard M, et al. JACC 2014;Nov 16:[Epub]